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Abstract: Pulmonary nodule formation is a frequent feature of
granulomatosis with polyangiitis (GPA). Traditional induction therapy
includes methotrexate or cyclophosphamide, however, pulmonary
nodules generally respond slower than vasculitic components of disease.
Efficacy of rituximab (RTX) solely for the treatment of pulmonary
nodules has not been assessed. In this observational cohort study, we
report patient outcomes with RTX in GPA patients with pulmonary
nodules who failed to achieve remission following conventional immu-
nosuppression. Patients (n¼ 5) with persistent pulmonary nodules were
identified from our clinic database and retrospectively evaluated.
Systemic manifestations, inflammatory markers, disease activity, con-
current immunosuppression, and absolute B cell numbers were recorded
pre-RTX and at 6 monthly intervals following treatment. Chest radio-
graphs at each time point were scored by an experienced radiologist,
blinded to clinical details. Five patients with GPA and PR3-ANCAwere
evaluated (2 male, 3 female), mean age 34 (22–52) years. Pulmonary
nodules (median 4, range 2–6), with or without cavitation were present
in all patients. RTX induced initial B cell depletion (<5 cells/mL) in all
patients but re-population was observed in 3 patients. Repeated RTX
treatment in these 3 and persistent B cell depletion in the whole cohort
was associated with further significant radiological improvement.
Radiographic scoring at each time interval showed reduction in both
number of nodules (P¼<0.0001) and largest nodule diameter
(P¼<0.0001) in all patients for at least 18 months following B cell
depletion. In summary, RTX therapy induces resolution of pulmonary
granulomatous inflammation in GPA following prolonged B cell
depletion.
(Medicine 93(27):e229)
Abbreviations: ANCA = anti-neutrophil cytoplasm antibody,FRCR, FRCP, Ch , DSc, FRCP,
RCP, and Alan D. Salama, PhD, FRCP
CD = cluster of differentiation, PR3 = proteinase-3, MPO =
myeloperoxidase, ENT = ear, nose and throat, VDI = vasculitis
damage index, BVAS = birmingham vasculitis activity score,
CRP = C-reactive protein, WCC = white cell count, Ig =
immunoglobulin, LDH = lactate dehydrogenase, CXR = chest x-
ray, ANOVA = analysis of variance, AZA = azathioprine, CYC =
cyclophosphamide, Fk = tacrolimus, IFXB = infliximab, IVIg =
intravenous immunoglobulin, MethylP = methylprednisolone,
MMF = mycophenolate mofetil, MTX = methotrexate, P =
prednisolone, HRCT = high resolution CT, Th = T helper, IL =
interleukin, TNF = tumour necrosis factor.
INTRODUCTION
A nti-neutrophil cytoplasm antibody (ANCA)-associatedsmall vessel vasculitis is characterized by life-threatening
inflammation of vascular beds, resulting in pulmonary haemor-
rhage, and rapidly progressive glomerulonephritis. Renal invol-
vement signals the development of severe generalized disease,
which untreated is associated with a mortality rate of over 85%.1
ANCA-associated vasculitis (AAV) encompasses the clinical
syndromes of granulomatosis with polyangiitis (GPA, formerly
Wegener’s granulomatosis), microscopic polyangiitis (MPA),
and eosinophilic granulomatosis with polyangiitis (EGPA).2
Most often, diagnosis is accompanied by circulating autoanti-
bodies directed against either proteinase-3 (PR3-ANCA) or
myeloperoxidase (MPO-ANCA), contained within azurophilic
granules or secretory vesicles in neutrophils and monocytes,
respectively.3 GPA and MPA are more common than EGPA,
and the latter is regarded to differ in pathogenesis, extent of
organ involvement, and frequency of ANCA detection.3
The presence of granulomatous inflammation of the upper
and lower respiratory tract is the hallmark of GPA and a
distinguishing feature from MPA on clinical presentation.
Localized granulomatous inflammation of the lungs, eyes or
ears, nose and throat (ENT) can progress to early systemic and
generalized disease with disseminated vasculitis, but also poses
significant disease burden to patients. Relapse rates reach up to
38% at 5 years in GPA, and PR3-ANCA, which is strongly
associated with GPA, acts an independent predictor of relapse.4
However, there is a lack of evidence base guiding treatment of
predominant granulomatous inflammation typically seen in
localized and early systemic disease and, given the relapsing
course of disease over time, much emphasis has been placed on
identifying less toxic treatments associated with better patient
tolerability and improved clinical efficacy.5,6
Recent trials have demonstrated equivalence of the mono-
clonal anti-CD20 antibody rituximab (RTX) with cyclopho-, suggestions of poorer outcomes for
us inflammation treated with RTX have
ted.9 In early, open-label prospective
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studies, a lack of efficacy of RTX on granulomatous disease
manifestations and variability in induction of remission of
refractory GPA was observed.10,11 Limited remission of pul-
monary lesions was also noted following comparison of the
effect of RTX on granulomatous and vasculitic manifestations
in GPA, with most patients showing some sign of improvement
although a proportion of patients did not respond to RTX at
all.12 By contrast, we and others have described success of RTX
therapy on retro-orbital,13 head, neck, and pulmonary manifes-
tations.14 However, the effect of RTX on specific radiographic
appearances of pulmonary granulomatous inflammation has not
been assessed and no insight as to what predicts outcome in
patients is established.
Here, we demonstrate the safe and effective resolution of
pulmonary granulomata in an observational cohort study of
patients with GPA resistant to conventional therapy who were
treated with RTX, at a reduced dosing regimen compared to
previous reports, and suggest that prolonged B cell depletion is
required for effective nodule resolution.
PATIENTS AND METHODS
Patients with early systemic GPA and persistent pulmonary
granulomatous lesions who required additional therapy and
were treated with RTX were identified from our multi-disci-
plinary vasculitis clinic and retrospectively evaluated. All
investigators abided by the ‘‘Ethical Principles for Medical
Research Involving Human Subjects’’ outlined in the Declara-
tion of Helsinki, and adopted in October 2000 by the World
Medical Association.
All patients fulfilled diagnostic criteria outlined by the
Chapel Hill Consensus Conference and the American College
Henderson et alof Rheumatology.2,15 Clinical characteristics, demographics,
and disease duration were recorded. Detailed history of previous
immunosuppressive treatment was established following review
TABLE 1. Clinical Characteristics of Patients Treated With RTX fo
Patient 1 2
Age 30 33
Gender Male Female
Disease duration (months) 62 28
Months to B cell repopulation 30 6
Follow-up (months) 38 18
BVAS 11 10
VDI 4 3
CRP (mg/L) 25 15
WCC (109/L) 12.1 9
Creatinine (mmol/L) 110 68
Immunosuppressants
previously used
CYC; IFXB; P;
MMF; AZA
P; MMF
Immunosuppressants at
start of RTX
P 20mg od AZA
75mg od
P 12.5mg od
MMF 1g od
Active organ involvement
at start of RTX
Pulmonary nodules,
rhinosinusitis,
subglottic stenosis
Pulmonary nodules,
bilateral main
bronchial narrowin
subglottic stenosis
Demographics, BVAS, VDI, baseline inflammatory markers, and serum c
alongside extent of active organ involvement.
AZA¼ azathioprine, BVAS¼Birmingham vasculitis activity score, C
IFXB¼ infliximab, IVIg¼ intravenous immunoglobulin, MethylP¼methy
P¼ prednisolone, RTX¼ rituximab, VDI¼ vasculitis damage index, WCC
2 | www.md-journal.comof clinical case records. RTX treatment was the same in all
patients and included 1 g boluses administered on 2 occasions,
2 weeks apart. Repopulation of peripheral blood B cells was
defined as >5 cells/mL following previous B cell depletion
(<5 cells/mL). A further course of RTX was administered
on an individual patient basis when clinical indication was
supported by B cell re-population.
Disease manifestations, organ involvement, vasculitis
damage index (VDI), and Birmingham vasculitis activity score
(BVAS)were recorded for each patient. C-reactive protein (CRP),
total white cell count (WCC), serum creatinine, and PR3-ANCA
titres were recorded in all patients. In addition, serum immuno-
globulins (IgG, IgA, and IgM) were documented. Lactate dehyd-
rogenase (LDH) was not routinely measured during treatment.
Chest x-rays (CXR), performed at 6 monthly intervals
throughout each patient’s treatment course, were scored by
an experienced radiologist blinded to clinical and radiological
details. Radiographic scoring was performed up until 18 months
(Patients 2, 4, and 5), 24 months (Patient 3), and 38 months
(Patient 1). Extent of pulmonary manifestations examined
included cavitating and non-cavitating pulmonary nodules,
largest nodule diameter, presence of fibrosis, or consolidation,
and presence of ancillary features such as pleural effusions.16
Analyses were performed using descriptive statistics and one-
way repeated measures ANOVA using GraphPad PrismTM.
RESULTS
Clinical Characteristics
We identified 5 patients (3 female, 2 male) with persistent
pulmonary nodules that had not responded to conventional
Medicine  Volume 93, Number 27, December 2014immunosuppression and were treated with RTX. Disease mani-
festations in all 5 patients were confined to the ENT, ocular,
and pulmonary systems, representing early systemic disease.17
r Persistent Pulmonary Granulomatosis Inflammation in GPA
3 4 5
33 22 52
Female Female Male
120 23 12
17 – –
24 28 20
12 13 10
2 2 4
19 98 14
12 9.2 15.7
101 55 93
P; AZA; MTX;
CYC; MMF; MethylP
CYC; P; AZA CYC; MethylP;
MTX; P
P 20mg od P 15mg od AZA
100mg od
P 10mg od MTX
15mg once weekly
g,
Pulmonary nodules,
septal perforation,
nasal crusting,
epistaxis
Pulmonary nodules,
nasal septal
granulomas,
secondary crusting
& obstruction
Pulmonary nodules,
sclerokeratitis,
retro-orbital
granuloma
reatinine are shown. In addition, immunosuppressant history is outlined
RP¼C-reactive protein, CYC¼ cyclophosphamide, Fk¼ tacrolimus,
l-prednisolone, MMF¼mycophenolate mofetil, MTX¼methotrexate,
¼white cell count.
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PR3-ANCA antibodies were present in all patients. Mean patient
age was 34 years (range 22–52). Disease duration, previous and
current immunosuppressants prior to administration of RTX are
summarized in Table 1. In addition, baseline VDI, BVAS, CRP,
creatinine, and total WCC are also shown in Table 1. Median
follow-up reached 22 months (range 18–38). There were no
infectious complications recorded in any patients during the
follow-up period. RTX was well tolerated with no adverse
reactions to drug infusion recorded. Hospitalization following
therapy did not occur in any patient.
Pulmonary Granulomata and Chest Radiography
All patients had pulmonary nodules; cavitating (n¼ 2) and
non-cavitating (n¼ 3). Nodules ranged in number, with a
median of 4 nodules per patient (range 2–6), and in size,
median 3.6 cm (largest diameter range 3–6.8 cm) prior to
treatment. Change in largest diameter of pulmonary nodules
in association with B cell depletion is shown in Figure 1. An
example of a typical chest radiograph is shown in Figure 2.
Arrows outline significant reduction in size and almost com-
plete resolution of inflammation in some nodules. Consolida-
tion (n¼ 1), fibrosis (n¼ 2), main bronchial stenosis (n¼ 1),
and pleural effusions (n¼ 1) were additional features noted in
some patients on initial chest radiology.
Peripheral Blood B Cell Depletion, Disease
Activity, and RTX Administration
Medicine  Volume 93, Number 27, December 2014Pre-treatment median BVAS score was 11 (10–13), VDI 3
(2–4), and mean CRP and WCC 34 (14–98)mg/L and 11.6
(9–15.7) 109 cells/L, respectively (Table 1). Peripheral blood
100
50
0
14
12
10
8
6
4
2
0
0               6             12            18            24            30            36
0                                 6                               12                               18
0                        6                       12                      18                      24
40
30
20
10
0
200
150
100
50
0
4
3
2
1
0
7
6
5
4
3
2
1
0
Months
Months
Months
Patient 1
Patient 2
Patient 3
RTX RTX
RTX
RTX
RTX
Interval
CT imaging
Ab
so
lu
te
 B
 c
el
l N
um
be
r (
ce
lls
/uL
)
CR
P 
(m
g/L
)
Ab
so
lu
te
 B
 c
el
l
N
um
be
r (
ce
lls
/uL
)
Ab
so
lu
te
 B
 c
el
l
N
um
be
r (
ce
lls
/uL
) Largest Nodular
D
iam
eter (cm)
Largest Nodular
D
iam
eter (cm)
Largest Nodular Diam
eter (cm)
BVAS Score
Total W
CC (x 10
9
 cells/l)
FIGURE 1. Change in peripheral blood B cell count after RTX (plotted a
(plotted against the right y axis) is shown for each patient. RTX adminis
B cell count 2 weeks after RTX therapy shows effective B cell depletio
# 2014 Lippincott Williams & WilkinsB cell depletion (<5 cells/mL) was achieved in all patients by
2 weeks following RTX administration. B cells remained
depleted at 6 months in 80% of patients. Further RTX was given
to 3 patients (Patients 1–3) based on each individual’s clinical
condition, radiological changes, and B cell repopulation.
Patient 1 repopulated peripheral B cells at 18 months after
initial RTX (104 cells/mL), however, clinically remained well,
and B cell return was not associated with an inflammatory
response (CRP 2mg/L,WCC 7.7 109 cells/L) or rise in BVAS
(6 at 18 months, 13 pre-treatment). Therefore, the patient was
monitored with interval imaging; at 18 months no change in size
or number of pulmonary nodules was found (Figure 1), while
high resolution CT (HRCT) performed at 24 months confirmed
no change in pulmonary nodules and apparent reduction in
mediastinal lymphadenopathy. The patient’s condition also
remained stable (CRP 2mg/L, WCC 9.4 109 cells/L and
BVAS 6). PR3-ANCA antibody titres were variable throughout
the treatment course but progressively increased to 420 units/
mL at 30 months (nadir 76 units/mL at 12 months) in associ-
ation with deterioration in clinical condition, with rise in BVAS
to 11, rise in inflammatory markers (CRP 98mg/L, WCC
12 109 cells/L), sustained B cell repopulation (84 cells/mL),
and persistent pulmonary nodules. Repeat RTX treatment was
initiated at 30 months and the patient successfully depleted
peripheral B cells within 2 weeks of administration.
B cell repopulation was observed at 6 months in Patient 2,
despite achieving B cell depletion following initial treatment.
Although a significant improvement in radiographic appear-
Rituximab in Pulmonary Granulomatosis With Polyangiitisances was observed at 6 months (Figure 2), the clinical
condition did not show the same response; BVAS was 10 at
6 months (13 pre-treatment), CRP 74mg/L, and WCC
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Henderson et al Medicine  Volume 93, Number 27, December 20149.4 109 cells/L. PR3-ANCA titres measured 69 units/mL pre-
RTX and 40 units/mL at 6 months. With ongoing disease
activity and signs of inflammation, further RTX was adminis-
tered and the patient similarly depleted peripheral B cells within
2 weeks of administration, which was sustained up until the
study end point at 18 months. This was associated with a
sustained reduction of BVAS (to 1), CRP (to 5mg/L), WCC
(to 9.4 109 cells/L), and pulmonary nodules.
After 12 months of therapy, B cell repopulation occurred in
Patient 3 (8 cells/mL) and further increased at 18 months
(166 cells/mL). BVASwas unchanged between 6 and 18 months
(11 at 6 and 18 months, 12 pre-treatment), but WCC increased
(12 109 cells/L) and CXR at 18 months showed persistent
pulmonary nodules with no evidence of infection. Therefore
RTX was re-administered at 18 months and the patient depleted
peripheral B cells as shown in Figure 1. CRP and PR3-ANCA
titres showed minimal change between 6 and 18 months; 9 to
15mg/L and 2 to 8 units/mL, respectively. BVAS reduced to
4 at 24 months.
In comparison, Patients 4 and 5 did not require any further
RTX over an 18-month period with sustained B cell depletion
after initial dosing. Prior to treatment, BVAS, CRP, and WCC
measured 12, 98mg/L and 9.2 109 cells/L, respectively in
Patient 4, and 16, 14mg/L and 15.7 109 cells/L, respectively
in Patient 5. Resolution of inflammatory markers continued in
both patients alongside B cell depletion. PR3-ANCA antibodies
measured 64 units/mL at 18 months in Patient 4. Of note in
Patient 5, PR3-ANCA antibody titre increased to 378 units/mL
at 18 months in the absence of an inflammatory response,
evidence of disease activity, or repopulation of peripheral B
cells. Throughout treatment course, no patient developed any
signs of renal involvement or intercurrent acute kidney injury
and serum creatinine measured, at each clinic visit, remained
within the normal reference range (data not shown).
Outcomes
Prolonged B cell depletion (<5 cells/mL) following RTX
was associated with significant reduction in number of pul-
monary nodules (P¼<0.0001) as well as size of the largest
nodule (P¼<0.0001) in all patients (pre-RTX to 18, 24, or 38
months post-RTX, respectively). BVAS reduced following
treatment, as outlined for each patient above, however, ‘‘grum-
FIGURE 2. Chest radiographs performed pre-rituximab and after
cavitating pulmonary nodule, which reduced in size from 3.6 to 2.
show almost complete resolution of a cavitating nodule present abling’’ ENT disease largely accounted for persistent disease
activity. Pre-treatment median BVAS score was 11 (10–13) and
post-treatment score was 4 (0–6), at 18 months (Patients 2, 4,
4 | www.md-journal.comand 5), 24 months (Patient 3), and 38 months (Patient 1),
respectively. There was no overall significant difference in
PR3-ANCA antibody concentration at 6 monthly intervals
after RTX. Mean glucocorticoid dose pre-RTX was 12.5mg
(7.5–20mg) which significantly decreased to a mean of 5mg
(5–7.5mg) at 6 months (P¼ 0.008) and 2.5mg (0–5mg) at the
study endpoint (P¼<0.0001). Additional maintenance immu-
nosuppression was not altered following RTX treatment.
Serial measurements of serum immunoglobulins were
available in 4 patients (Patients 1–4). Mean serum IgG con-
centration measured 11.9 (9.9–14.6) g/L, 11.8 (8.7–13.2) g/L,
12.8 (7.8–18.3) g/L, and 11.5 (8.7–13.1) g/L at 0, 6, 12, and 18
months, respectively. Mean serum IgA concentration measured
2 (0.85–2.97) g/L, 1.8 (0.64–2.65) g/L, 1.7 (0.8–2.3) g/L, and
1.7 (0.8–2.7) g/L at 0, 6, 12, and 18 months, respectively. Mean
IgM serum concentration measured 0.8 (0.1–1.5) g/L, 0.6 (0.2–
1) g/L, 0.5 (0.2–0.8) g/L, and 0.4 (0.2–0.6) g/L at 0, 6, 12, and
18months, respectively. Additional RTX treatment in Patients 1
and 3 after 18 months did not result in any further decrease
in immunoglobulins.
DISCUSSION
Although this represents a small retrospective (selected)
series of patients, our data confirm that RTX is effective for
treatment of pulmonary granulomas following a prolonged
period of B cell depletion. Significant clinical improvement
was delayed and took up to 2 years for complete radiological
resolution of the nodules in some patients. BVAS score also
improved after treatment, however, persistent ENT symptoms
were scored as disease activity and it is worth considering the
difficulty in clinically distinguishing between active disease and
tissue damage and therefore BVAS may in fact over emphasize
extent of disease activity after RTX. Nevertheless, our results
demonstrate that in 5 patients with GPA, RTX improved
pulmonary granulomatous manifestations when given in
addition to standard therapy and allowed a significant reduction
in corticosteroid usage.
RTX has been shown to be equally effective in treatment
of ANCA negative GPA, suggesting that its effects are
mediated in part via immune mechanisms distinct from auto-
antibody production. B cell depletion is therefore an attractive
therapeutic strategy for treating granulomatous manifestations
months in Patient 2 are shown. Far left arrows show the largest
after treatment. The downward arrows to the right of each CXR
e start of treatment.of GPA. Granulomata consist of neutrophils, giant cells,
monocyte-derived tissue macrophages, B cells and
CD4þCD28 T cells.18 The activation of T cells in an
# 2014 Lippincott Williams & Wilkins
unbalanced Th1 phenotype and maturation of dendritic cells
by PR3, exaggerating this Th1 response, have previously
highlighted Th1 cells as critical mediators of granuloma
pathogenesis in GPA.18,19 Indeed, both CD4þ Th1 and
Th17 cells have been implicated as important orchestrators
of granulomatous inflammation.
B cells also appear to play an important role in GPA
granuloma pathogenesis. Significant B cell populations have
been described within pulmonary granulomatous nodules and B
cells have been shown to influence both monocyte and T cell
activation. Whilst this study used peripheral blood B cell counts
as an indicator of B cell repopulation, and this does not
necessarily represent the proportion of B cells contained within
pulmonary granulomata, it is becoming clearer that the balance
of B cell subsets, particularly following RTX, is important in
determining clinical outcome.20 Our group have characterized
B cell subsets in AAV, by relative expression of CD24 and
CD38. The balance of B cell subsets is altered after RTX and
this altered phenotype is associated with decreased T cell
activation and increased IL-10 production in vitro.21
It is therefore interesting to consider patients in whom B
cells repopulated in the circulation, without supporting evi-
dence of active inflammation. This was particularly apparent in
Patient 1 where peripheral B cells repopulated but without a
change in disease activity and radiological features showing
stable and, to some extent resolving, inflammation. Evidence of
worsening disease activity then developed 12 months later
alongside sustained B cell repopulation and rising PR3-ANCA
antibody titres. Phenotypic changes in repopulated B cells could
account for this change in clinical course. This also emphasizes
the additional benefit of RTX therapy in AAV, providing an
opportunity to restore B cell homeostasis amidst an arsenal of
autoantibody production against self-antigens and immune cell
activation. In comparison, Patient 3 demonstrated significant
PR3-ANCA antibody production without evidence of periph-
eral B cell repopulation, which emphasizes the need to consider
granulomata in GPA as B cell containing tertiary lymphoid
structures pivotal to driving the relapsing disease course.
Over the preceding decade, randomized controlled trials
have standardized approaches to induction of remission and
maintenance therapy.6 However, despite continuing improve-
ment in patient outcomes with generalized disease, treatment of
early systemic disease, and particularly granulomatous inflam-
mation, confined to the respiratory and ENT tracts is not
supported by the same evidence base to guide clinical prac-
tice.22 Disease relapse also remains common and PR3-ANCA
antibody positivity, most often associated with GPA, and
cardiac involvement are recognized as independent risk factors
for relapse. In addition, serum creatinine shows a paradoxical
inverse relationship with disease relapse; higher serum creati-
nine levels are associated with lower risk of relapse.4 Therefore,
although localized and early systemic GPA lack organ or life-
threatening manifestations, persistent granulomatous inflam-
mation is difficult to treat and exposes patients to significant
risks associated with long-term immunosuppression.23
The use of methotrexate, in combination with glucocorti-
coids, has been advocated following a randomized controlled
trial, which demonstrated its equivalence at inducing remission
in early systemic disease compared to oral cyclophosphamide.
However, time to remission in patients with pulmonary invol-
vement was increased, overall time to relapse was reduced and
Medicine  Volume 93, Number 27, December 2014rate of relapse was greater in the methotrexate group, with
notable adverse drug effects in each group.24 The beneficial
effect of co-trimoxazole, alone or in combination with
# 2014 Lippincott Williams & Wilkinsglucocorticoids, at achieving remission in localized GPA has
been reported in single centre cohort studies.25–27 Similarly,
rate of relapse remained high and additional immunosuppres-
sion was required in the majority of patients.28,29 Numerous
biologic therapies have also been evaluated for refractory (most
often defined as progressive disease unresponsive to conven-
tional therapy, such as glucocorticoids and cyclophosphamide)
and persistent disease.6 While cohort studies outline the use of
deoxyspergualin, anti-thymocyte globulin, and TNF-alpha
antagnosists, there is a greater level of evidence supporting
the use of intravenous immunoglobulin and RTX for refractory
and persistent disease.1,30–34
It is important to consider the impact of RTX on more than
just B cell numbers. Whilst no apparent effect on immunoglo-
bulins is observed after a single dose of RTX, IgM levels reduce
over time and repeated dosing is associated with depletion of
IgG levels and impaired humoral immune responses.35–38
Monitoring of serum immunoglobulin levels during prolonged
treatment is therefore important.
In non-Hodgkin’s lymphoma, from which the use of RTX
originated, 4 RTX doses at 4 weekly intervals administered at
375mg/m2 was shown to achieve peripheral B cell depletion for
up to 6 months, after which gradual re-population of CD20-
positive B cells was detectable. Clinical responsewas also shown
to be influenced by serum antibody half-life, with values ranging
from 12.7 to 370.8 hours following this standard infusion proto-
col.39 Previous reports in AAV have similarly employed 4 RTX
doses at 4 weekly intervals administered at 375mg/m2.10–12
However, in our series, we demonstrate that a standardized
reduced dose of RTX (1g boluses administered on 2 occasions,
2 weeks apart) at less frequent intervals, remains effective in
maintaining B cell depletion with some patients not requiring any
further B cell depletion therapy over an 18-month follow-up
period. We therefore propose that maintaining depletion of B
cells is a safer approach and guides individual patient response
and improvement in pulmonary granulomatous manifestations in
persistent disease, rather than total RTX dose administered.
There is no question that the efficacy of RTX on granu-
lomatous lesions in GPA has not always been apparent,9,11 and
it is clear that granulomatous features respond less rapidly than
vasculitis features.12 Additionally, initial reports of resolution
of granulomata with RTX were complicated by the co-admin-
stration of high-dosemethylprednisolone.12 In our cohort, B cell
depletion and improvement in granulomatous inflammation is
unequivocally related to RTX, as methylprednisolone was not
administered, concurrent immunosuppressive agents were not
altered and we achieved a statistically significant reduction in
prednisolone dosage following sustained B cell depletion.
Treatment of granulomatous lesions, in addition to the
vasculitic component of GPA, is critical to inducing disease
remission and minimizing patient morbidity, but is often harder
to achieve and frequently entails the use of cyclophosphamide.
RTX is now considered an effective treatment of refractory head
and neck manifestations with remission rates reaching more
than 80% in small cohort studies.34 This case series further
develops the efficacy profile of RTX and supports cyclopho-
sphamide avoidance in appropriate patients by providing a
rationale for use of a reduced dosing regimen of RTX in
persistent pulmonary granulomatous inflammation.
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